Neuronostics

We're having some great conversations here at the International League Against Epilepsy (ILAE) conference in Liverpool, exploring how innovative digital solutions like BioEP™ can integrate with current clinical practice to help drive improvements in patient outcomes. Come to stand S11 and have a chat with one of the Neuronostics team!   And you can find out more tomorrow morning at our symposium presentation: A digital decision support tool for epilepsy: What is it and how does it impact clinical decision making? We will discuss the current evidence around a novel digital biomarker derived from background EEG called BioEP™. We’ll cover a range of important topics: 💠 Introduction to BioEP™ & overview of a large-scale, multisite retrospective study validating BioEP on clinically inconclusive EEGs (John Terry) 💠 Findings from a belief-updating study at the Royal Wolverhampton highlighting how BioEP™ has impacted decision-making confidence among specialist nurses in a first seizure clinic (Phil Tittensor)

We are looking forward to meeting everyone over the next 3 days at the ILAE British Branch meeting. Our co-founders John Terry and Wessel Woldman are here, alongside our BioEP product owner Anke Verhaege. Come and visit our stand and don’t forget breakfast is on offer at our symposium on Wednesday at 8:30am where we will be sharing some of the research findings that underpin BioEP and hearing from Phil Tittensor about its utility in clinic!

We are pleased to share that we have been shortlisted for two awards at The Tech South West Awards, taking place on November 21st 2024. 🎉 Neuronostics is in the running for: ⭐ Growth Award ⭐ Healthtech Award Tech South West are a member organisation dedicated to helping support, connect and showcase the tech sector across the South West. The Tech South West Awards recognise and celebrate the huge variety of innovation taking place across the South West tech ecosystem. We look forward to attending and celebrating alongside all the other talented organisations who were shortlisted. 

If you are attending the International League Against Epilepsy conference, then join us for breakfast at the Neuronostics Symposium: A digital decision support tool for epilepsy: What is it and how does it impact clinical decision making? Neuronostics will be at the ILAE conference in Liverpool from Monday 21st to Wednesday 23rd October. The symposium will take place on October 23rd from 8:30-9:15. We will discuss the current evidence around a novel digital biomarker derived from background EEG called BioEP™. We’ll cover a range of important topics: 💠 Introduction to BioEP™ & Neuronostics (John Terry) 💠 Overview of a large-scale, retrospective, multi-site NIHR Portfolio study validating BioEP™ on clinically inconclusive EEGs (Wessel Woldman) 💠 Early findings from a belief-updating study at the Royal Wolverhampton highlighting how BioEP™ has impacted decision-making confidence among specialist nurses during routine diagnostics (Phil Tittensor) As well as the symposium, we’ll be at Stand S11 on the exhibition floor - feel free to visit us to learn more about BioEP™ and discuss how you might evaluate this technology in your own clinical setting.

Our ECLIPSE trial has received Research Ethics Committee (REC) approval! This was the last step in pre-trial set up and we can now begin the exciting phase of initiating sites in readiness for patient recruitment. The ECLIPSE study, supported by Innovate UK, is a multi-centre, observational trial that will investigate how changes in the BioEP score relate to treatment response during anti-seizure medication titration. Our goal is to address a key challenge in epilepsy treatment: the uncertainty around how effective anti-seizure medications are. By using the BioEP score, we aim to provide an objective marker to help clinicians and patients make more informed decisions. Over the next few months, we will be setting up sites across the UK and preparing for patient recruitment. Stay tuned for updates on this exciting journey as we work towards improving epilepsy management and patient outcomes. 

We would like to introduce and warmly welcome Kate Daw, Neuronostics’ new Research and Development Intern. Kate is a neuroscientist working across our R&D & clinical departments. Kate has preclinical research experience from her time working at the University of Bristol, exploring the potential of psychedelics as anti-depressants, in collaboration with industry. Welcome to the team Kate – it’s great to have you on board! 👏

We would like to introduce Anke Verhaege, Neuronostics’ new Product Owner. With a double background as both a medical doctor and a biomedical engineer, Anke bridges clinical insights and technical development. By collaborating closely with clinicians and engineers, she ensures BioEP is scientifically robust and meets real-world healthcare needs. Welcome to the team Anke – it’s great to have you onboard! 🎉

Neuronostics wins the 2024 Epilepsy Foundation Shark Tank competition! Last week, co-founder Prof John Terry attended the Epilepsy Foundation’s Pipeline Conference in Atlanta and took part in the Shark Tank competition. Inspired by the American equivalent of Dragon’s Den, this competition attracts entrepreneurs, scientists, and clinicians from around the world who are developing novel approaches to address the challenges of epilepsy. John presented alongside four other finalists, each facing sharp questions from the panel of five Sharks. Pitches were assessed on the science behind their ideas and their commercial plan, as well as the potential of the technology to meaningfully impact people with epilepsy and their families. After an animated debate, Neuronostics secured the support of two Sharks and the public vote bringing the prize to $125,000! These funds will be used to accelerate our US market launch, with the goal of securing approval from the US Food and Drug Administration (FDA). Our heartfelt thanks to all who voted for us and to the Epilepsy Foundation for endorsing our technology. We look forward to attending in 2025 to update the conference on the impact our technology is having. Read more here: https://lnkd.in/eSgcdUtM

We’ll be in London this Thursday for an ERIUK Navigator Workshop where our co-founder Dr Wessel Woldman has co-organised a one-day workshop on data science in the space of epilepsy, with a particular focus on translation and interdisciplinary learnings. For attendees, the team will be on hand to answer any questions you may have.

Neuronostics Webinar: BioEP™ - a decision support tool that unlocks the full potential of EEG    We are pleased to invite you to our BioEP™ webinar coming up on September 24th at 19:00. We’re excited to explore how BioEp™ can provide support in the diagnosis of suspected epilepsy. We’ll be discussing the potential for BioEP™ to improve care pathways through: - Prioritising those most in need for follow-up EEGs improving caseload management and easing the burden on neurophysiology departments.  - Improving confidence in decision making through a quantitative rating of the support for an epilepsy diagnosis from any EEG.  - Decreasing A&E admissions due to uncontrolled seizures with earlier, more accurate diagnosis.  - Reducing waiting times for people with suspected epilepsy by expediting diagnostic processes. We’ve got an amazing panel lined up, including John Terry, Wessel Woldman, and Phil Tittensor. John and Wessel will introduce Neuronostics, and share their insights on the research underpinning BioEP™. Phil will be sharing his own experiences using BioEP™ in his clinical practice—something we think you’ll really enjoy!    If you’re interested, just follow the registration link below to sign up and add us to your calendar.      It would be great to have you join us! https://lnkd.in/ecqPVXdC